Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neoplasms 2Ureteral Neoplasms 2Carcinoma, Transitional Cell 2Urothelial Cancer 1Urologic Neoplasms 1Urethral Neoplasms 1Triple Negative Breast Neoplasms 1Metastatic Urothelial Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2durvalumab 2vinflunine 1tremelimumab 1enfortumab vedotin 1avelumab 1Sunitinib 1Radiotherapy 1Paclitaxel 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urothelial Cancer × enfortumab vedotin × Clear all
NCT04223856 2026-05-29

EV-302

Astellas Pharma Inc

Phase 3 Active not recruiting
886 enrolled 12 charts 1 FDA
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡